title: Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies.
abstract: BACKGROUND
  Studies have shown that skeletal muscle and adipose tissue are linked to overall survival (OS) and progression-free survival (PFS). Because targeted therapies have improved the outcome in patients with metastatic renal cell carcinoma (mRCC), new prognostic parameters are required. The objective of the current study was to analyze whether body composition parameters play a prognostic role in patients with mRCC.
  
  
  METHODS
  Adipose tissue, skeletal muscle, and skeletal muscle density (SMD) were assessed with computed tomography imaging by measuring cross-sectional areas of the tissues and mean muscle Hounsfield units (HU). A high level of mean HU indicates a high SMD and high quality of muscle. OS and PFS were estimated using the Kaplan-Meier method and compared with the log-rank test. The multivariable Cox proportional hazards model was adjusted for Heng risk score and treatment.
  
  
  RESULTS
  In the 149 patients studied, the median OS was 21.4 months and was strongly associated with SMD; the median OS in patients with low SMD was approximately one-half that of patients with high SMD (14 months vs 29 months; P = .001). After adjustment for Heng risk score and treatment, high SMD was associated with longer OS (hazards ratio, 1.85; P = .004) and longer PFS (hazards ratio, 1.81; P = .002). Adding SMD will separate the intermediate-risk and favorable-risk groups into 3 groups, with different median OS periods ranging from 8 months (95% confidence interval [95% CI], 6 months-12 months) for an intermediate-risk Heng score/low SMD to 22 months (95% CI, 14 months-27 months) for an intermediate-risk Heng score/high SMD and a favorable-risk Heng score/low SMD to 35 months (95% CI, 24 months-43 months) for a favorable-risk Heng score/high SMD.
  
  
  CONCLUSIONS
  High muscle density appears to be independently associated with improved outcome and could be integrated into the prognostic scores thereby enhancing the management of patients with mRCC.
authors.affiliation: Department of Ambulatory Care, Institut Gustave-Roussy, Villejuif, France.
authors.forename: Sami
authors.initials: S
authors.lastname: Antoun
authors.forename: Emilie
authors.initials: E
authors.lastname: Lanoy
authors.forename: Roberto
authors.initials: R
authors.lastname: Iacovelli
authors.forename: Laurence
authors.initials: L
authors.lastname: Albiges-Sauvin
authors.forename: Yohann
authors.initials: Y
authors.lastname: Loriot
authors.forename: Mansouriah
authors.initials: M
authors.lastname: Merad-Taoufik
authors.forename: Karim
authors.initials: K
authors.lastname: Fizazi
authors.forename: Mario
authors.initials: M
authors.lastname: di Palma
authors.forename: Vickie E
authors.initials: VE
authors.lastname: Baracos
authors.forename: Bernard
authors.initials: B
authors.lastname: Escudier
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001823:Body Composition; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000473:pathology*; D002986:Clinical Trials as Topic; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D018482:Muscle, Skeletal / Q000473:pathology*; D009362:Neoplasm Metastasis; D009536:Niacinamide / Q000031:analogs & derivatives / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000627:therapeutic use; D011379:Prognosis; D000077157:Sorafenib; D016019:Survival Analysis; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib
keywords: body composition; muscle density; prognosis; renal cell carcinoma; targeted therapy